Clinical trial designs incorporating predictive biomarkers. (February 2016)

• Record Type: Journal Article
• Authors: Renfro, Lindsay A.; Mallick, Himel; An, Ming-Wen; Sargent, Daniel J.; Mandrekar, Sumithra J.
• Is Part Of: Cancer treatment reviews. Volume 43(2016)
• Page Start: 74
• Page End: 82
• Publication Date: 2016-02
• Subjects: Clinical trial design -- Adaptive trial design -- Biomarker-based design -- Bayesian adaptive design -- Enrichment designs -- Targeted therapies; Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2015.12.008
• Languages: English
• ISSNs: 0305-7372

Abstract

Highlights: Cancer is becoming increasingly understood and defined on the molecular level. A changing paradigm for cancer treatment mandates development of new trial designs. A number of biomarker-based designs, both simple and complex, have been proposed. Designs that can both evaluate and validate new biomarkers on trial still needed. Abstract: Development of oncologic therapies has traditionally been performed in a sequence of clinical trials intended to assess safety (phase I), preliminary efficacy (phase II), and improvement over the standard of care (phase III) in homogeneous (in terms of tumor type and disease stage) patient populations. As cancer has become increasingly understood on the molecular level, newer "targeted" drugs that inhibit specific cancer cell growth and survival mechanisms have increased the need for new clinical trial designs, wherein pertinent questions on the relationship between patient biomarkers and response to treatment can be answered. Herein, we review the clinical trial design literature from initial to more recently proposed designs for targeted agents or those treatments hypothesized to have enhanced effectiveness within patient subgroups (e.g., those with a certain biomarker value or who harbor a certain genetic tumor mutation). We also describe a number of real clinical trials where biomarker-based designs have been utilized, including a discussion of their respective advantages and challenges. As cancers become further categorized and/or reclassified according to individual patient and tumor features, we anticipate a continued need for novel trial designs to keep pace with the changing frontier of clinical cancer research.